rhTPO in Critical Patients With Thrombocytopenia
Overview
The primary objectives of this study are to assess the impact of rhTPO on mortality among severe sepsis patients with thrombocytopenia, as well as changes of platelet counts and platelet transfusion rates.
Full Title of Study: “A Randomized, Open-label, Placebo-controlled, Multi-center Study to Evaluate Safety and Efficacy of Recombinant Human Thrombopoietin Among Severe Sepsis Patients With Thrombocytopenia”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: March 2016
Detailed Description
Thrombocytopenia is prevalent among critical patients who is admitted to intensive care unit. Researches have shown that thrombocytopenia is associated with mortality among those patients. Currently, no standard therapy exist for critical patients with Thrombocytopenia. In 2012 SSC guideline, platelet transfusion is induced for thrombocytopenia in critical patients for reducing the risk of bleeding. However, indication for platelet transfusion is relatively strict. No early intervention could be done according to this guideline. Previous studies have shown that recombinant human thrombopoietin can reduce severe sepsis with low platelet 28-day mortality in patients with hyperlipidemia, effectively improve peripheral platelet number, reducing the probability of platelet transfusion.The primary objectives of this study are to assess the impact of rhTPO on mortality among severe sepsis patients with thrombocytopenia, as well as changes of platelet counts and platelet transfusion rates.
Interventions
- Drug: TPO
- rhTPO(Recombinant Human Thrombopoietin,TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China), 15000U/ml, s.c injection
- Drug: control
- Normal saline,1ml/day, s.c injection
Arms, Groups and Cohorts
- Experimental: TPO
- rhTPO(Recombinant Human Thrombopoietin,TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China), 15000U/ml, s.c injection
- Placebo Comparator: control
- Normal saline,1ml/day, s.c injection
Clinical Trial Outcome Measures
Primary Measures
- Mortality
- Time Frame: 28-day after enrolled
Secondary Measures
- Time to recover to a normal platelet level
- Time Frame: 10 days
- Occurrence of bleeding event
- Time Frame: 10 days
- 7-day survival rate
- Time Frame: 7 days
- Number of Participants who survived from thrombocytopenia
- Time Frame: 10 days
- Occurrence of platelet transfusion
- Time Frame: 10 days
- Total amount of platelet transfusion
- Time Frame: 10 days
- Percentage of participants with platelet response
- Time Frame: 10 days
- Platelet response was defined as platelet counts 50 x 10^9/L, measured at each study visit up to the end of the study period
- Time to platelet response
- Time Frame: 10 days
Participating in This Clinical Trial
Inclusion Criteria
- Patients would be include if Diagnosed as sepsis according to ACCP/CCM criteria Platelet counts is less than 50×109/L for 2 continues days Patient or legally authorized representative able to provide informed consent Exclusion Criteria:
- Subject has had a splenectomy for any reason Subject has an active malignancy who is now under chemotherapy Subject has a known history of bone marrow stem cell disorder Subject is receiving other investigational agents or procedures Subject is currently enrolled in, or has completed within the last 30 days, another investigational device or drug study Subject is pregnant or breast feeding Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and does not have a legally acceptable representative Subject has any kind of disorder that compromises the ability of the subject to comply with study procedures Subject is less than 18 years or more than 85 years of age History of bone marrow, lung, liver, pancreas, or small-bowel transplantation Acute pancreatitis with no established source of infection
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 85 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Jinling Hospital, China
- Provider of Information About this Clinical Study
- Principal Investigator: Jianan Ren, Vice president of General Surgery Department – Jinling Hospital, China
- Overall Official(s)
- Jianan Ren, Study Chair, Department of general surgery, Nanjing Jinling hospital
- Overall Contact(s)
- Qin Wu, MD, +86-15195916755, qinwu0221@gmail.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.